Familial hypercholesterolaemia and COVID-19: A two-hit scenario for endothelial dysfunction amenable to treatment

Atherosclerosis - Tập 320 - Trang 53-60 - 2021
Alpo Vuorio1,2, Frederick Raal3, Markku Kaste4, Petri T. Kovanen
1Mehiläinen Airport Health Centre, 01530, Vantaa, Finland
2University of Helsinki, Department of Forensic Medicine, 00014 Helsinki, Finland
3Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa
4Department of Neurosciences, Neurology, University of Helsinki, Department of Neurology, Neurocenter, Helsinki University Hospital, Helsinki, Finland

Tài liệu tham khảo

Wilemon, 2020, Reducing the clinical and public health burden of familial hypercholesterolemia: a global call to action, JAMA Cardiol, 5, 217, 10.1001/jamacardio.2019.5173 1999 Brown, 1981, Regulation of plasma cholesterol by lipoprotein receptors, Science, 212, 628, 10.1126/science.6261329 Tada, 2015, Assessment of coronary atherosclerosis in patients with familial hypercholesterolemia by coronary computed tomography angiography, Am. J. Cardiol., 115, 724, 10.1016/j.amjcard.2014.12.034 Ose, 1999, An update on familial hypercholesterolaemia, Ann. Med., 31, 13, 10.1080/07853890.1999.11904394 Humphries, 2018, Coronary heart disease mortality in treated familial hypercholesterolaemia: update of the UK Simon Broome FH register, Atherosclerosis, 274, 41, 10.1016/j.atherosclerosis.2018.04.040 Luirink, 2019, 20-Year follow-up of statins in children with familial hypercholesterolemia N, Engl. J. Med., 381, 1547, 10.1056/NEJMoa1816454 Wang, 2020, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China, J. Am. Med. Assoc., 323, 1061, 10.1001/jama.2020.1585 Sijbrands, 2001, Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study, BMJ, 322, 1019, 10.1136/bmj.322.7293.1019 Vuorio, 1997, Familial hypercholesterolemia in the Finnish North Karelia: a molecular, clinical, and genealogical study, Arterioscler. Thromb. Vasc. Biol., 17, 3127, 10.1161/01.ATV.17.11.3127 Netea, 1996, Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections, J. Clin. Invest., 97, 1366, 10.1172/JCI118556 Barkas, 2020, Diet and cardiovascular disease risk among individuals with familial hypercholesterolemia: systematic review and meta-analysis, Nutrients, 12, 2436, 10.3390/nu12082436 Khovidhunkit, 2000, Infection and inflammation‐induced proatherogenic changes of lipoproteins, J. Infect. Dis., 181, S462, 10.1086/315611 Kovanen, 2005, Drug therapies to prevent coronary plaque rupture and erosion: present and future Chow, 2020, Acute cardiovascular events associated with influenza in hospitalized adults: a cross-sectional study, Ann. Intern. Med., 10.7326/M20-1509 Kontula, 1999, Association of seropositivity for Chlamydia pneumoniae and coronary artery disease in heterozygous familial hypercholesterolaemia, Lancet, 354, 46, 10.1016/S0140-6736(99)01691-8 Hu, 1999, The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae, J. Clin. Invest., 103, 747, 10.1172/JCI4582 Nieto, 1997, Cytomegalovirus infection, lipoprotein(a), and hypercoagulability: an atherogenic link?, Arterioscler. Thromb. Vasc. Biol., 17, 1780, 10.1161/01.ATV.17.9.1780 DiMinno, 1986, Increased fibrinogen binding to platelets from patients with familial hypercholesterolemia, Arteriosclerosis, 6, 203, 10.1161/01.ATV.6.2.203 Vuorio, 2020, Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities, J. Intern. Med., 287, 2, 10.1111/joim.12981 Apostolou, 2010, Acute infection with Epstein-Barr virus is associated with atherogenic lipid changes, Atherosclerosis, 212, 607, 10.1016/j.atherosclerosis.2010.06.006 Sorensen, 1994, Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level, J. Clin. Invest., 93, 50, 10.1172/JCI116983 Charakida, 2009, Inflammatory and thrombotic processes are associated with vascular dysfunction in children with familial hypercholesterolemia, Atherosclerosis, 204, 532, 10.1016/j.atherosclerosis.2008.09.025 Vuorio A, Kovanen PT. Prevention of endothelial dysfunction and thrombotic events in COVID-19 patients with familial hypercholesterolemia. J. Clin. Lipidol. Published 15 Jun 2020. 10.1016/j.jacl.2020.06.006. Libby, 2020, COVID-19 is, in the end, an endothelial Disease, Eur. Heart J., 41, 3038, 10.1093/eurheartj/ehaa623 Nordestgaard, 2013, Eur. Heart J., 34, 10.1093/eurheartj/eht273 Sturm, 2018, Clinical genetic testing for familial hypercholesterolemia: JACC Scientific Expert Panel, J. Am. Coll. Cardiol., 72, 662, 10.1016/j.jacc.2018.05.044 Steinberg, 1997, Endothelial dysfunction is associated with cholesterol levels in the high normal range in humans, Circulation, 96, 3287, 10.1161/01.CIR.96.10.3287 Vuorio, 2016, Rescue therapy with PCSK9 inhibitors for patients with delayed diagnosis of heterozygous familial hypercholesterolemia: redressing the balance of missed opportunities, J. Clin. Lipidol., 10, 1278, 10.1016/j.jacl.2016.07.003 Tada, 2015, Assessment of coronary atherosclerosis in patients with familial hypercholesterolemia by coronary computed tomography angiography, Am. J. Cardiol., 115, 724, 10.1016/j.amjcard.2014.12.034 Caballero, 2012, Detection of subclinical atherosclerosis in familial hypercholesterolemia using non-invasive imaging modalities, Atherosclerosis, 222, 468, 10.1016/j.atherosclerosis.2012.02.043 Libby, 2019, Reassessing the mechanisms of acute coronary syndromes, Circ. Res., 124, 150, 10.1161/CIRCRESAHA.118.311098 Sahebkar, 2016, Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms, Br. J. Clin. Pharmacol., 81, 1175, 10.1111/bcp.12905 Pradhan, 2018, Residual inflammatory risk on treatment with PCSK9 inhibition on statin therapy, Circulation, 138, 141, 10.1161/CIRCULATIONAHA.118.034645 Humphries, 2019, Coronary heart disease mortality in severe vs. non-severe familial hypercholesterolaemia in the Simon Broome Register, Atherosclerosis, 281, 207, 10.1016/j.atherosclerosis.2018.11.014 Varga, 2020, Endothelial cell infection and endotheliitis in COVID-19, Lancet, 395, 1417, 10.1016/S0140-6736(20)30937-5 Khovidhunkit, 2004, Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host, J. Lipid Res., 45, 1169, 10.1194/jlr.R300019-JLR200 Boffa, 2019, Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease, Nat. Rev. Cardiol., 16, 305, 10.1038/s41569-018-0153-2 Besseling, 2015, Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus, J. Am. Med. Assoc., 313, 1029, 10.1001/jama.2015.1206 Barron, 2020, Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study, Lancet Diabetes Endocrinol, 20 Vuorio, 2016, Statins and new‐onset diabetes mellitus – a risk lacking in familial hypercholesterolaemia, J. Intern. Med., 279, 358, 10.1111/joim.12405 Humphries, 2018, The UK paediatric familial hypercholesterolaemia register: statin-related safety and 1-year growth data, J. Clin. Lipidol., 12, 25, 10.1016/j.jacl.2017.11.005 Pérez de Isla, 2016, Coronary heart disease, peripheral arterial disease, and stroke in familial hypercholesterolaemia: insights from the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study), Arterioscler. Thromb. Vasc. Biol., 36, 2004, 10.1161/ATVBAHA.116.307514 Kunutsor, 2020, Incidence of venous and arterial thromboembolic complications in COVID-19: a systematic review and meta-analysis, Thromb. Res., 196, 27, 10.1016/j.thromres.2020.08.022 Lodigiani, 2020, Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy, Thromb. Res., 191, 9, 10.1016/j.thromres.2020.04.024 Bilaloglu, 2020, Thrombosis in hospitalized patients with COVID-19 in a New York city health system, J. Am. Med. Assoc., 324, 799, 10.1001/jama.2020.13372 Beyrouti, 2020, Characteristics of ischaemic stroke associated with COVID-19, J. Neurol. Neurosurg. Psychiatry, 91, 889, 10.1136/jnnp-2020-323586 Oxley, 2020, Large-vessel stroke as a presenting feature of Covid-19 in the young, N. Engl. J. Med., 382, e60, 10.1056/NEJMc2009787 Rothstein, 2020, Acute cerebrovascular events in hospitalized COVID-19 patients, Stroke, 10.1161/STROKEAHA.120.030995 Andjelkovic, 2019, Endothelial targets in stroke, Arterioscler. Thromb. Vasc. Biol., 39, 2240, 10.1161/ATVBAHA.119.312816 Mao, 2020, Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China, JAMA Neurology, 77, 683, 10.1001/jamaneurol.2020.1127 Ntaios G, Michel P, Georgiopoulos G, Guo Y, Li W, Xiong J et al. Characteristics and outcomes in patients with COVID-19 and acute ischemic stroke: the global COVID-19 stroke registry. Stroke. Published 9 July 2020. doi: 10.1161/STROKEAHA.120.031208. Kaste, 1988, Risk of brain infarction in familial hypercholesterolemia, Stroke, 19, 1097, 10.1161/01.STR.19.9.1097 Cron, 2020, Coronavirus is the trigger, but the immune response is deadly, Lancet Rheumatol, 2, e370, 10.1016/S2665-9913(20)30165-X Paliogiannis, 2020, D-Dimer concentrations and COVID-19 severity: a systematic review and meta-analysis, Front. Public Health., 4, 432, 10.3389/fpubh.2020.00432 Shakoory, 2016, Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial, Crit. Care Med., 44, 275, 10.1097/CCM.0000000000001402 Cummings, 2020, Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study, Lancet, 395, 1763, 10.1016/S0140-6736(20)31189-2 Terpos, 2020, Hematological findings and complications of COVID‐19, Am. J. Hematol., 95, 834, 10.1002/ajh.25829 Moore, 2020, Cytokine release syndrome in severe COVID-19, Science, 368, 473, 10.1126/science.abb8925 Léonard-Lorant, 2020, Acute pulmonary embolism in COVID-19 patients on CT angiography and relationship to D-dimer levels, Radiology, 293, E189, 10.1148/radiol.2020201561 Mucha, 2020, Coagulopathy in COVID-19. Cleve, Clin. J. Med. Off. Yuan, 2015, Statins may decrease the fatality rate of Middle East respiratory syndrome infection, mBio, 6, 10.1128/mBio.01120-15 Vandermeer, 2012, Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study, J. Infect. Dis., 205, 13, 10.1093/infdis/jir695 Mehra, 2020, Cardiovascular disease, drug therapy, and mortality in Covid-19, N. Engl. J. Med., 382, e102, 10.1056/NEJMoa2007621 de Spiegeleer, 2020, The effects of ARBs, ACEIs and statins on clinical outcomes of COVID-19 infection among nursing home residents, J. Am. Med. Dir. Assoc., 21, 909, 10.1016/j.jamda.2020.06.018 Loppnow, 2011, Statins potently reduce the cytokine‐mediated IL6 release in SMC/MNC cocultures, J. Cell Mol. Med., 15, 994, 10.1111/j.1582-4934.2010.01036.x de Bont, 2006, LPS-induced release of IL-1 beta, IL-1Ra, IL-6, and TNF-alpha in whole blood from patients with familial hypercholesterolemia: no effect of cholesterol-lowering treatment, J. Interferon Cytokine Res., 26, 101, 10.1089/jir.2006.26.101 Wiklund, 2002, Effects of simvastatin and atorvastatin on inflammation markers in plasma, J. Intern. Med., 251, 338, 10.1046/j.1365-2796.2002.00966.x Cicek, 2016, Statins and IL-1β, IL-10, and MPO levels in gingival crevicular fluid: preliminary results, Inflammation, 39, 1547, 10.1007/s10753-016-0390-7 Liberale, 2019, IL-1β and statin treatment in patients with myocardial infarction and diabetic cardiomyopathy, J. Clin. Med., 8, 1764, 10.3390/jcm8111764 Schol‐Gelok, 2018, Clinical effects of antiplatelet drugs and statins on D‐dimer levels, Eur. J. Clin. Invest., 48, 10.1111/eci.12944 Adams, 2013, Statin therapy and levels of hemostatic factors in a healthy population: the Multi‐Ethnic Study of Atherosclerosis, J. Thromb. Haemostasis, 11, 1078, 10.1111/jth.12223 Dujovne, 2000, Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients, Am. J. Cardiol., 85, 350, 10.1016/S0002-9149(99)00745-6 Sbarouni, 2000, Effects of simvastatin or hormone replacement therapy, or both, on fibrinogen, factor VII, and plasminogen activator inhibitor levels in postmenopausal women with proven coronary artery disease, Am. J. Cardiol., 86, 80, 10.1016/S0002-9149(00)00831-6 Undas, 2005, Statins and blood coagulation, Arterioscler. Thromb. Vasc. Biol., 25, 287, 10.1161/01.ATV.0000151647.14923.ec Undas, 2014, Anticoagulant effects of statins and their clinical implications, Thromb. Haemostasis, 111, 392, 10.1160/TH13-08-0720 Ekholm, 2015, Haemostatic and inflammatory alterations in familial hypercholesterolaemia, and the impact of angiotensin II infusion, J. Renin-Angiotensin-Aldosterone Syst. JRAAS, 16, 328, 10.1177/1470320315575848 Meretoja, 2014, Stroke thrombolysis: save a minute, save a day, Stroke, 45, 1053, 10.1161/STROKEAHA.113.002910 Huxley, 2003, Risk of fatal stroke in patients with treated familial hypercholesterolemia: a prospective registry study, Stroke, 34, 22, 10.1161/01.STR.0000047123.14312.3E Barkas, 2015, Statins decrease the risk of stroke in individuals with heterozygous familial hypercholesterolemia: a systematic review and meta-analysis, Atherosclerosis, 243, 60, 10.1016/j.atherosclerosis.2015.08.038 Powers, 2019, Stroke, 50, e344, 10.1161/STROKEAHA.118.022606 Kow CS, Hasan SS. Meta-analysis of effectiveness of statins in patients with severe COVID-19 Am. J. Cardiol.. Published 12 Aug 2020;doi:10.1016/j.amjcard.2020.08.004. Zhang XJ, Qin JJ, Cheng X, Shen L, Zhao Y-CX, Yuan Y et al. In-hospital Use of Statins Is Associated with Reduced Mortality Among Individuals with COVID-19. Cell. Metab. Published 24 June 2020. doi.org/10.1016/j.cmet.2020.06.015. Grasselli, 2020, Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern. Med., 10.1001/jamainternmed.2020.3539 Iqbal Z, Ho JH, Adam S, France M, Syed A, Neely D et a. Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK, Atherosclerosis, https://doi.org/10.1016/j.atherosclerosis.2020.09.008. Banach, 2020, FH Europe and the International Lipid Expert Panel (ILEP). Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic, Pharmacol. Res., 158, 10.1016/j.phrs.2020.104891 Choudry, 2020, High thrombus burden in patients with COVID-19 presenting with ST-Segment elevation myocardial infarction, J. Am. Coll. Cardiol., 76, 1168, 10.1016/j.jacc.2020.07.022 Tsimikas, 2020, Statins and increases in Lp(a): an inconvenient truth that needs attention, Eur. Heart J., 41, 192, 10.1093/eurheartj/ehz776 Vuorio, 2020, PCSK9 inhibitors for COVID-19: an opportunity to enhance the antiviral action of interferon in patients with hypercholesterolemia, J. Intern. Med. Vuorio, 2020, Familial hypercholesterolaemia and COVID‐19: triggering of increased sustained cardiovascular risk, J. Intern. Med., 287, 746, 10.1111/joim.13070 Sjouke, 2015, Homozygous autosomal dominant hypercholesterolaemia: prevalence, diagnosis and current and future treatment perspectives, Curr. Opin. Lipidol., 26, 200, 10.1097/MOL.0000000000000179 Cuchel, 2014, Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society, Eur. Heart J., 35, 2146, 10.1093/eurheartj/ehu274 Clerkin, 2020, COVID-19 and cardiovascular disease, Circulation, 141, 1648, 10.1161/CIRCULATIONAHA.120.046941 Jeon, 2018, Cholesterol is important for the entry process of porcine delta-coronavirus, Arch. Virol., 163, 3119, 10.1007/s00705-018-3967-7 Holven, 2014, Subjects with familial hypercholesterolemia are characterized by an inflammatory phenotype despite long-term intensive cholesterol lowering treatment, Atherosclerosis, 233, 561, 10.1016/j.atherosclerosis.2014.01.022 Kraft, 2000, Lipoprotein(a) in homozygous familial hypercholesterolemia, Arterioscler. Thromb. Vasc. Biol., 20, 522, 10.1161/01.ATV.20.2.522 Pourahmad, 2020, Efficacy of plasmapheresis and immunoglobulin replacement therapy (IVIG) on patients with COVID-19. SN, Compr. Clin. Med., 2, 1407, 10.1007/s42399-020-00438-2 Brown, 1978, Prenatal diagnosis of homozygous familial hypercholesterolaemia. Expression of a genetic receptor disease in utero, Lancet, 8063, 526, 10.1016/S0140-6736(78)90552-4 Vuorio, 1997, Neonatal diagnosis of familial hypercholesterolemia in newborns born to a parent with a molecularly defined heterozygous familial hypercholesterolemia, Arterioscler. Thromb. Vasc. Biol., 17, 3332, 10.1161/01.ATV.17.11.3332 de Jongh, 2002, Family history of cardiovascular events and endothelial dysfunction in children with familial hypercholesterolemia, Atherosclerosis, 163, 193, 10.1016/S0021-9150(02)00003-5 Bifulco M, Gazzerro P. Statin therapy in COVID-19 infection: much more than a single pathway. Eur. Heart J. Cardiovasc. Pharmacother. Published 12 Juni 2020. doi:10.1093/ehjcvp/pvaa055. Castiglione, 2020, Statin therapy in COVID-19 infection, Eur. Heart J. Cardiovasc. Pharmacother., 6, 258, 10.1093/ehjcvp/pvaa042 Dashti‐Khavidaki, 2020, Considerations for statin therapy in patients with COVID‐19, Pharmacotherapy, 40, 484, 10.1002/phar.2397 Mehta, 1998, Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease, J. Am. Coll. Cardiol., 31, 1217, 10.1016/S0735-1097(98)00093-X Vuorio, 2019, Statins for children with familial hypercholesterolemia, Cochrane Database Syst. Rev., 11 Rudski, 2020, Multimodality imaging in evaluation of cardiovascular complications in patients with COVID-19: JACC Scientific Expert Panel, J. Am. Coll. Cardiol., 76, 1345, 10.1016/j.jacc.2020.06.080 Vuorio A, Kovanen PT. Statins as adjuvant therapy for COVID-19 to calm the stormy immunothrombosis and beyond. Published 4 Dec 2020. Front. Pharmacol.. doi: 10.3389/fphar.2020.579548.